Summary
Cardiac amyloidosis is a rare disease associated with poor prognosis. Although there is some evidence that cardiac surgery can be offered to select patients with concomitant valve disease, outcomes following surgical revascularization are universally poor. Even in highly selected patients surgical intervention is difficult to justify, and percutaneous options must be preferred.